Wilmington Savings Fund Society FSB Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Wilmington Savings Fund Society FSB raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 193.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,810 shares of the biopharmaceutical company’s stock after purchasing an additional 1,193 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Regeneron Pharmaceuticals were worth $1,903,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Sachetta LLC increased its position in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. Stephens Consulting LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $26,000. FSA Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth about $26,000. Finally, Family Firm Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent research reports. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Leerink Partners reissued a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Wells Fargo & Company decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.90.

Regeneron Pharmaceuticals Trading Down 1.3 %

Shares of Regeneron Pharmaceuticals stock opened at $731.30 on Friday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $728.68 and a twelve month high of $1,211.20. The firm has a market capitalization of $80.36 billion, a PE ratio of 18.10, a P/E/G ratio of 2.32 and a beta of 0.08. The firm’s 50-day moving average price is $849.77 and its 200 day moving average price is $1,003.80.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.